Mark Pollack to Pseudomonas Infections
This is a "connection" page, showing publications Mark Pollack has written about Pseudomonas Infections.
Connection Strength
0.827
-
Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharide-specific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol. 2000; 44(8):629-35.
Score: 0.175
-
Pharmacodynamic and protective properties of a murine lipopolysaccharide-specific monoclonal antibody in experimental Pseudomonas aeruginosa pneumonia in mice. Microbiol Immunol. 1991; 35(12):1131-41.
Score: 0.094
-
The virulence of Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct; 6 Suppl 3:S617-26.
Score: 0.061
-
Immunization with Pseudomonas aeruginosa high-molecular-weight polysaccharides prevents death from Pseudomonas burn infections in mice. Infect Immun. 1984 Feb; 43(2):759-60.
Score: 0.058
-
Enhanced survival in Pseudomonas aeruginosa septicemia associated with high levels of circulating antibody to Escherichia coli endotoxin core. J Clin Invest. 1983 Dec; 72(6):1874-81.
Score: 0.057
-
Clinical significance of serum antibody responses to exotoxin A and type-specific lipopolysaccharides in patients with Pseudomonas aeruginosa infections. Am J Med. 1983 Jun; 74(6):980-7.
Score: 0.055
-
Pseudomonas aeruginosa exotoxin A. N Engl J Med. 1980 Jun 12; 302(24):1360-2.
Score: 0.045
-
Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979 Feb; 63(2):276-86.
Score: 0.041
-
Mechanism of action of Pseudomonas aeruginosa exotoxin A in experimental mouse infections: adenosine diphosphate ribosylation of elongation factor 2. Infect Immun. 1978 Jan; 19(1):29-33.
Score: 0.038
-
Serum antibody to Pseudomonas aeruginosa exotoxin measured by a passive hemagglutination assay. J Clin Microbiol. 1977 Jul; 6(1):58-61.
Score: 0.037
-
Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection. Invest Ophthalmol Vis Sci. 1997 Jun; 38(7):1418-25.
Score: 0.037
-
Neutralizing antibody to Pseudomonas aeruginosa exotoxin in human sera: evidence for in vivo toxin production during infection. Infect Immun. 1976 Oct; 14(4):942-7.
Score: 0.035
-
Therapeutic effects of a human antiflagella monoclonal antibody in a neutropenic murine model of Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 1993 Feb; 37(2):164-70.
Score: 0.027
-
In vitro and in vivo functional activities of monoclonal antibodies reactive with Pseudomonas aeruginosa serogroup 6 lipopolysaccharides. Antibiot Chemother (1971). 1991; 44:163-71.
Score: 0.023
-
The outlook for prevention and treatment of infections due to Pseudomonas aeruginosa. Rev Infect Dis. 1984 Sep-Oct; 6 Suppl 3:S769-74.
Score: 0.015
-
Antibody activity against Pseudomonas aeruginosa in immune globulins prepared for intravenous use in humans. J Infect Dis. 1983 Jun; 147(6):1090-8.
Score: 0.014
-
Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun. 1977 Dec; 18(3):596-602.
Score: 0.009
-
Functionally active monoclonal antibody that recognizes an epitope on the O side chain of Pseudomonas aeruginosa immunotype-1 lipopolysaccharide. Infect Immun. 1986 Sep; 53(3):656-62.
Score: 0.004